Breast magnetic resonance imaging for monitoring response to therapy.
There is no difference in disease-free or overall survival in patients who undergo adjuvant versus neoadjuvant chemotherapy. Thus, neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer who would like to consider breast conservation, and is also the primary treatment in patients with inflammatory breast cancer. Magnetic resonance has emerged as the most sensitive imaging modality to assess the response of tumor to neoadjuvant chemotherapy.
University of California San Diego Moores Cancer Center, La Jolla, CA 92093, USA. hojeda@ucsd.edu
Haydee
H
Ojeda-Fournier
Jade
J
de Guzman
Nola
N
Hylton
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Breast cancer; Breast conservation; Magnetic resonance imaging; Mammography; Neoadjuvant chemotherapy; Pathologic complete response; Response prediction; Ultrasound